Stock Scorecard



Stock Summary for Viking Therapeutics Inc (VKTX) - $82.00 as of 3/28/2024 10:13:27 PM EST

Total Score

8 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VKTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VKTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VKTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for VKTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for VKTX

2 Top Biotech Buyout Candidates 3/28/2024 5:55:00 PM
Market Shows Breadth As Leaders Take A Breath: Weekly Review 3/28/2024 2:52:00 PM
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates 3/28/2024 12:33:00 PM
5 Things You Need to Know If You Buy Viking Therapeutics Stock Today 3/28/2024 9:50:00 AM
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Viking Therapeutics ( NASDAQ:VKTX ) 3/27/2024 5:15:00 PM
Viking ( VKTX ) Up 17% on Encouraging Oral Obesity Drug Data 3/27/2024 4:42:00 PM
Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats 3/27/2024 4:22:00 PM
Here's Why Ozempic And Mounjaro Rivals Won't Topple Drugmakers Novo Nordisk And Eli Lilly Anytime Soon 3/27/2024 10:26:00 AM
Why Viking Therapeutics Stock Is Skyrocketing Today 3/26/2024 3:28:00 PM
Viking jumped 25% on early weight loss pill data. We still prefer Eli Lilly 3/26/2024 3:23:00 PM

Financial Details for VKTX

Company Overview

Ticker VKTX
Company Name Viking Therapeutics Inc
Country USA
Description Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 4/24/2024

Stock Price History

Last Day Price 82.00
Last Day Price Updated 3/28/2024 10:13:27 PM EST
Last Day Volume 4,292,491
Average Daily Volume 9,981,512
52-Week High 99.41
52-Week Low 8.28
Last Price to 52 Week Low 890.34%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -13.93
Free Cash Flow Ratio 24.48
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 19.19
Total Cash Per Share 3.35
Book Value Per Share Most Recent Quarter 3.48
Price to Book Ratio 21.43
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 107,930,000
Market Capitalization 8,850,260,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -24.73%
Reported EPS 12 Trailing Months -0.91
Reported EPS Past Year -0.92
Reported EPS Prior Year -0.91
Net Income Twelve Trailing Months -85,895,000
Net Income Past Year -85,895,000
Net Income Prior Year -68,867,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%

Balance Sheet

Total Cash Most Recent Quarter 362,079,000
Total Cash Past Year 362,079,000
Total Cash Prior Year 155,485,000
Net Cash Position Most Recent Quarter 362,079,000
Net Cash Position Past Year 362,079,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 348,419,000
Total Stockholder Equity Prior Year 145,322,000
Total Stockholder Equity Most Recent Quarter 348,419,000

Options

Put/Call Ratio 0.20
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 6.49
MACD Signal 9.20
20-Day Bollinger Lower Band -13.27
20-Day Bollinger Middle Band 31.10
20-Day Bollinger Upper Band 75.46
Beta 1.06
RSI 59.57
50-Day SMA 21.33
200-Day SMA 9.64

System

Modified 3/27/2024 9:54:35 AM EST